CCL21 and neoplasm: Given the plethora of studies highlighting the important role of CCL21 in recruitment of immune effector cells and subsequent tumor immunity and the paucity of studies to support enhanced Treg recruitment to the tumor via CCL21/CCR7, it is highly unlikely that selective targeting of this pathway as a means to prevent Treg recruitment will be of clinical benefit in cancer patients.